177 related articles for article (PubMed ID: 17911401)
1. Activin receptor-like kinase-2 inhibits activin signaling by blocking the binding of activin to its type II receptor.
Renlund N; O'Neill FH; Zhang L; Sidis Y; Teixeira J
J Endocrinol; 2007 Oct; 195(1):95-103. PubMed ID: 17911401
[TBL] [Abstract][Full Text] [Related]
2. Mullerian inhibiting substance recruits ALK3 to regulate Leydig cell differentiation.
Wu X; Zhang N; Lee MM
Endocrinology; 2012 Oct; 153(10):4929-37. PubMed ID: 22872577
[TBL] [Abstract][Full Text] [Related]
3. Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.
Clarke TR; Hoshiya Y; Yi SE; Liu X; Lyons KM; Donahoe PK
Mol Endocrinol; 2001 Jun; 15(6):946-59. PubMed ID: 11376113
[TBL] [Abstract][Full Text] [Related]
4. Growth differentiation factor-9 signaling is mediated by the type I receptor, activin receptor-like kinase 5.
Mazerbourg S; Klein C; Roh J; Kaivo-Oja N; Mottershead DG; Korchynskyi O; Ritvos O; Hsueh AJ
Mol Endocrinol; 2004 Mar; 18(3):653-65. PubMed ID: 14684852
[TBL] [Abstract][Full Text] [Related]
5. The serine/threonine transmembrane receptor ALK2 mediates Müllerian inhibiting substance signaling.
Visser JA; Olaso R; Verhoef-Post M; Kramer P; Themmen AP; Ingraham HA
Mol Endocrinol; 2001 Jun; 15(6):936-45. PubMed ID: 11376112
[TBL] [Abstract][Full Text] [Related]
6. Insight into Molecular Mechanism for Activin A-Induced Bone Morphogenetic Protein Signaling.
Xie C; Jiang W; Lacroix JJ; Luo Y; Hao J
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899497
[TBL] [Abstract][Full Text] [Related]
7. Activins bind and signal via bone morphogenetic protein receptor type II (BMPR2) in immortalized gonadotrope-like cells.
Rejon CA; Hancock MA; Li YN; Thompson TB; Hébert TE; Bernard DJ
Cell Signal; 2013 Dec; 25(12):2717-26. PubMed ID: 24018044
[TBL] [Abstract][Full Text] [Related]
8. Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression.
Zhan Y; Fujino A; MacLaughlin DT; Manganaro TF; Szotek PP; Arango NA; Teixeira J; Donahoe PK
Development; 2006 Jun; 133(12):2359-69. PubMed ID: 16687449
[TBL] [Abstract][Full Text] [Related]
9. BMPR2 inhibits activin and BMP signaling via wild-type ALK2.
Olsen OE; Sankar M; Elsaadi S; Hella H; Buene G; Darvekar SR; Misund K; Katagiri T; Knaus P; Holien T
J Cell Sci; 2018 Jun; 131(11):. PubMed ID: 29739878
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation regulation of the interaction between Smad7 and activin type I receptor.
Liu X; Nagarajan RP; Vale W; Chen Y
FEBS Lett; 2002 May; 519(1-3):93-8. PubMed ID: 12023024
[TBL] [Abstract][Full Text] [Related]
11. High-density lipoproteins affect endothelial BMP-signaling by modulating expression of the activin-like kinase receptor 1 and 2.
Yao Y; Shao ES; Jumabay M; Shahbazian A; Ji S; Boström KI
Arterioscler Thromb Vasc Biol; 2008 Dec; 28(12):2266-74. PubMed ID: 18948634
[TBL] [Abstract][Full Text] [Related]
12. Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival.
Chauvin M; Garambois V; Choblet S; Colombo PE; Chentouf M; Gros L; De Brauwere DP; Duonor-Cerutti M; Dumas K; Robert B; Jarlier M; Martineau P; Navarro-Teulon I; Pépin D; Chardès T; Pèlegrin A
Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 34013359
[TBL] [Abstract][Full Text] [Related]
13. Activin receptor-like kinase 2 and Smad6 regulate epithelial-mesenchymal transformation during cardiac valve formation.
Desgrosellier JS; Mundell NA; McDonnell MA; Moses HL; Barnett JV
Dev Biol; 2005 Apr; 280(1):201-10. PubMed ID: 15766759
[TBL] [Abstract][Full Text] [Related]
14. Activins and inhibins and their signaling.
Vale W; Wiater E; Gray P; Harrison C; Bilezikjian L; Choe S
Ann N Y Acad Sci; 2004 Dec; 1038():142-7. PubMed ID: 15838109
[TBL] [Abstract][Full Text] [Related]
15. Activin stimulates CYP19A gene expression in human ovarian granulosa cell-like KGN cells via the Smad2 signaling pathway.
Nomura M; Sakamoto R; Morinaga H; Wang L; Mukasa C; Takayanagi R
Biochem Biophys Res Commun; 2013 Jul; 436(3):443-8. PubMed ID: 23747729
[TBL] [Abstract][Full Text] [Related]
16. Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2.
Macías-Silva M; Hoodless PA; Tang SJ; Buchwald M; Wrana JL
J Biol Chem; 1998 Oct; 273(40):25628-36. PubMed ID: 9748228
[TBL] [Abstract][Full Text] [Related]
17. Bone morphogenetic proteins.
Chen D; Zhao M; Mundy GR
Growth Factors; 2004 Dec; 22(4):233-41. PubMed ID: 15621726
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of steroidogenesis in Leydig cells by Müllerian-inhibiting substance.
Fynn-Thompson E; Cheng H; Teixeira J
Mol Cell Endocrinol; 2003 Dec; 211(1-2):99-104. PubMed ID: 14656482
[TBL] [Abstract][Full Text] [Related]
19. Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer.
Basal E; Ayeni T; Zhang Q; Langstraat C; Donahoe PK; Pepin D; Yin X; Leof E; Cliby W
Curr Mol Med; 2016; 16(3):222-31. PubMed ID: 26917267
[TBL] [Abstract][Full Text] [Related]
20. Cell-type specific regulation of myostatin signaling.
Kemaladewi DU; de Gorter DJ; Aartsma-Rus A; van Ommen GJ; ten Dijke P; 't Hoen PA; Hoogaars WM
FASEB J; 2012 Apr; 26(4):1462-72. PubMed ID: 22202673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
